Browse Articles

Discover research articles across all indexed journals

LRRC71 is essential for sperm motility, fertilization, and male fertility

Journal of Biological Chemistry Lu Yuan, Chuan Xu, Tingting Ge et al. Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113176

Hepatic arterial infusion chemotherapy plus immune checkpoint inhibitors and lenvatinib for locally advanced biliary tract cancer: A single-arm, exploratory study.

Journal of Clinical Oncology Tianci Wang, Chenxuan Fu, Jingwen Zhang et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.108

108 Background: Immune checkpoint inhibitors (ICIs) plus gemcitabine and cisplatin (GemCis) have become a standard first-line systemic treatment for advanced biliary tract cancers (BTCs). However, prognosis remains limited. Hepatic arterial infusion chemotherapy (HAIC) delivers high concentrations of cytotoxic agents directly to tumors, providing improved locoregional control, particularly in patients intolerant of systemic chemotherapy. In this prospective clinical study, we evaluated the preliminary clinical efficacy and safety of GemCis-HAIC plus ICIs and lenvatinib in patients with locally advanced BTCs. Methods: Eligible patients had locally advanced BTCs, with tumor lesions confined to the abdominal cavity, and were intolerant of or refused intravenous systemic chemotherapy. All patients received ICIs and lenvatinib plus GemCis-HAIC for up to six cycles according to response and tolerability. The primary endpoint was objective response rate (ORR). Results: As of December 2025, 10 patients were enrolled. The median age was 68 years (range, 36–71), with intrahepatic cholangiocarcinoma (iCCA) in 4 patients, perihilar cholangiocarcinoma (pCCA) in 5, and gallbladder cancer (GBC) in 1; At baseline, 30% had extrahepatic metastases, 80% had multifocal disease, and 30% had chronic viral hepatitis (HBV/HCV). Regarding treatment exposure, 70% of patients received ≥4 cycles of HAIC. ICIs included camrelizumab (n=5), adebrelimab (n=3), and durvalumab (n=2). Among 8 patients evaluable for response, 3 patients achieved partial response, 4 patients had stable disease, including 1 successfully converted to surgical resection, and 1 had progressive disease, yielding an ORR of 37.5% and a DCR of 87.5%. The median PFS was 5.29 months (95% CI, 2.34-8.24). Overall, 60% of patients experienced treatment-related adverse events (TRAEs), and grade 3 TRAEs occurred in 30% of patients, mainly elevated γ-glutamyl transferase (GGT). Conclusions: GemCis-HAIC plus ICIs and Lenvatinib showed promising antitumor activity with manageable toxicity in patients with BTCs. This regimen warrants further investigation as a potential first-line option in this population. Clinical trial information: ChiCTR2400091470 .

Uncovering and Engineering Mixed-Valence States in Blatter-Type Radicals on Au(111)

Journal of the American Chemical Society Ruoning Li, Peng-Yi Liu, Zi-Cong Wang et al. Jul 01, 2026 DOI: 10.1021/jacs.6c06053

A large-scale benchmark shows lightweight models can distinguish matched from mismatched problem–solution pairs across diverse STEM disciplines

Scientific Reports Nicolas Douard, Ahmed Samet, George Giakos et al. Jul 01, 2026 DOI: 10.1038/s41598-026-60058-z

Liver Tissueoid on‐a‐Chip Modeling Liver Regeneration and Allograft Rejection (Adv. Mater. 37/2026)

Advanced Materials Abdul Rahim Chethikkattuveli Salih, Arne Peirsman, Danial Khorsandi et al. Jul 01, 2026 DOI: 10.1002/adma.73798

GRP75 chaperone-driven mitochondria–ER membrane coupling promotes Ca2+-dependent ROS accumulation and ferroptosis during hypoxic stress

Journal of Biological Chemistry Haoxiao Yan, Penggeng Chen, Yaoyi Zhang et al. Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113215

Tri-specific immune checkpoint engineering: Clinical translation of HCB301 targeting SIRPα, PD-L1, and TGF.

Journal of Clinical Oncology Ji Zhu, William Jeffery Edenfield, Hongyan Tong et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.tps90

TPS90 Background: Tumor immune escape arises from coordinated suppression across innate, adaptive, and stromal compartments, including PD-1/PD-L1-mediated T-cell inhibition, CD47-SIRPα-mediated suppression of macrophage phagocytosis, and TGF-β-driven immune exclusion within the tumor microenvironment. Therapeutic strategies targeting single or dual pathways may incompletely address this layered resistance architecture. HCB301 was developed following clinical translation of SIRPα-based macrophage checkpoint targeting to extend modulation across multiple nonredundant resistance mechanisms within a single biologic molecule. HCB301 is a first-in-class tri-specific IgG4 Fc fusion protein integrating an anti-PD-L12 domain, an engineered high-affinity SIRPα variant to disrupt CD47 signaling, and a mutant TGF-β receptor II ligand trap designed to sequester active TGF-β isoforms. Preclinical evaluation demonstrated simultaneous engagement of all three targets, restoration of PD-1/PD-L1 T-cell signaling, enhancement of macrophage-mediated phagocytosis without erythrocyte engulfment, and selective inhibition of TGF-β-induced Smad2 phosphorylation, and coordinated immune activation in humanized xenograft and transgenic tumor models. These findings support tri-axis immune checkpoint modulation as a strategy to remodel the tumor microenvironment. Methods: HCB301-101 (NCT06487624) is an open-label, multicenter Phase 1 dose-escalation study enrolling patients with advanced solid tumors or relapsed/refractory classical Hodgkin lymphoma. The study employs a Bayesian Optimal Interval (BOIN) design to evaluate escalating intravenous dose levels. Primary objectives are safety, tolerability, and determination of the maximum tolerated dose and/or the recommended Phase 2 dose. Secondary objectives include pharmacokinetics, pharmacodynamic assessment of pathway modulation, and antitumor activity. Exploratory analyses include immune profiling to characterize coordinated modulation of macrophage, T-cell, and stromal compartments. Enrollment is ongoing. Clinical trial information: NCT06487624 .

Off–On–Off Probes for Precise Theranostics

Journal of the American Chemical Society Yufu Tang, Bin Liu Jul 01, 2026 DOI: 10.1021/jacs.6c09013

Seed germination and seedling growth of spring bread wheat recombinant inbred lines (RILs) under PEG-induced drought stress

Scientific Reports Somayeh Khalili Kolikand, Seyed Abolghasem Mohammadi, Mahmood Torchi Jul 01, 2026 DOI: 10.1038/s41598-026-60166-w

Abstract Wheat is one of the staple foods, and its importance is considerable on a global scale. Drought stress significantly affects wheat seed germination. The absence of drought-resistant wheat varieties affects wheat cultivation, especially in arid regions of the world. This study examined seed germination and seedling growth of 147 wheat genotypes subjected to moisture stress induced by polyethylene glycol (PEG). All studied traits showed significant reduction in stress environment in comparison to control (PEG-0%), while MGT and RSR showed increase under stressful condition. The genotype (G), PEG-Treatments (TPEG), and G × TPEG(T PEG ), and the G × T PEG interactions had significant effects on all studied traits ( p  < 0.01), implying considerable variation of genes among the RILs. PCA and cluster analysis revealed a good distinction between tolerant and susceptible genotypes. Elite RILs retained their high SVI, RL, and SHL even in severe osmotic stress conditions, which is a great opportunity for use of those lines in the development of drought tolerant varieties through breeding programs. Nevertheless, PEG osmotic stress is not similar to field drought conditions, and thus the results obtained are indicative of osmotic stress response only. The described genotypic variation represents a very good basis for further QTL and marker-assisted breeding work for improved drought resistance in bread wheat.

Breaking Energy Density‐Stress Trade‐Off in Anode‐Free Lithium Pouch Cells

Advanced Materials Kun Qin, Liangdong Lin, Kai Jiang et al. Jul 01, 2026 DOI: 10.1002/adma.73652

ABSTRACT The swelling of the Li metal anode and its adverse impacts have barred lithium metal batteries (LMBs) from practical applications. Owing to insufficient recognition of the energy density–stress trade‐off, no viable solution has emerged to halt their expansion or diminish their internal stress accumulation (SA) while preserving their exceptional energy density. We proposed principle‐based criteria to guide the development of high‐energy and low‐swelling LMBs by defining the boundary parameters of strain‐buffering techniques. Taking a typical space‐adaptive buffering (SAB) layer as an example, we have materialized this criterion and verified its scientific validity and forward‐looking nature, effectively reducing SA and mitigating the local stress concentration (SC). As a result, the Ah‐level NCM9 (LiNi x Co y Mn 1‐x‐y O 2 , x ≥ 0.9)||SAB‐Cu pouch cell prototype with the high bare‐cell energy densities of 465 Wh/kg and 1330 Wh/L exhibits the uniform stress distribution and low SC (extreme difference in local pressure<2 MPa), avoiding the failure of Li dendrite puncture. Furthermore, the Ah‐level NCM811(Li 1.2 Ni 0.8 Co 0.1 Mn 0.1 O 2 )||SAB‐Cu pouch cell demonstrates a perfect trade‐off among energy densities (418 Wh/kg and 1061 Wh/L), cycle life (164 cycles with 77% capacity retention), SA (<2 MPa), and swelling ratio (3.6%), underscoring the practical feasibility of the SAB‐AF‐LMB.

Sirtuin 5 knockdown induced the ferroptosis of hepatic stellate cells in hepatic fibrosis progression through de-succinylation modification of GPX4

Journal of Biological Chemistry Jun Zhou, Jinjuan Zhang, Shan Zheng et al. Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113366

Blinded <sup>18</sup> FDG PET-CT re-read versus EBUS-TBNA in stage III <sub>A-C</sub> NSCLC: A mediastinal staging concordance study.

Journal of Clinical Oncology Kratika Bhatia, Manoj Gupta, Aman Gupta et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.280

280 Background: 18 FDG PET-CT is standard for mediastinal staging of NSCLC, but its specificity is low in tuberculosis-endemic regions. Because EBUS-TBNA is an imperfect reference standard, we quantified agreement and directional discordance between PET and EBUS cytology. Methods: This retrospective, blinded diagnostic concordance study included 52 patients with biopsy-confirmed stage III A-C NSCLC who underwent both PET-CT and EBUS-TBNA for initial mediastinal staging. A nuclear medicine specialist, blinded to original reports and EBUS results, re-interpreted de-identified PET-CT DICOM images. EBUS-TBNA served as the imperfect reference standard. Primary endpoint was station-level agreement quantified by Cohen’s κ with patient-cluster bootstrap 95% CIs. Secondary analyses included overall agreement, Byrt/Bishop/Carlin prevalence and bias indices, station-group strata (N2 vs N1) and echelon strata. Station-level diagnostic metrics were estimated with cluster-bootstrap CIs. Patient-level N2/N3 positivity concordance used standard κ and exact McNemar’s test. Discordance characterization compared SUV max and short-axis diameter between PET+/EBUS+ vs PET+/EBUS− stations (Wilcoxon). SUV max discrimination for EBUS positivity was assessed by ROC AUC (DeLong and cluster-bootstrap CIs) and Youden thresholds. Sensitivity analyses tested varying EBUS sensitivity assumptions. Results: Station-level agreement was slight (κ = 0.177; 95% CI: −0.008 to 0.371), with 42.3% discordance. The discordance pattern was anatomically asymmetric: at N2 mediastinal stations (n = 88), κ was 0.255 (fair agreement), driven by PET+/EBUS− discordance (33% FP vs 7% FN) and at N1 hilar stations (n = 16), κ was −0.125, driven by PET−/EBUS+ discordance (44% FN vs 13% FP). Echelon-stratified analysis showed best agreement at echelon 2 (subcarinal/ipsilateral station 4; κ = 0.301) with FP-dominant error, and symmetric poor agreement at echelon 3 (contralateral mediastinum; κ = 0.111). At the patient level, PET showed 91.7% concordance sensitivity but only 35.7% specificity for N2/N3 disease, with strongly directional discordance (McNemar’s p = 0.0004). PET+/EBUS− stations had significantly lower SUV max (median 5.4 vs 8.8, p = 0.002) and smaller nodes (median 12 vs 18 mm, p &lt; 0.001) than concordant positives. Of 13 PET−/EBUS+ stations, 84.6% had no visible node on PET. ROC analysis yielded an AUC of 0.760 (95% CI: 0.627–0.890); the Youden-optimal threshold (SUV max &gt; 7.2) achieved 80.0% specificity versus 11.1% at the traditional 2.5 cutoff. Imperfect-reference sensitivity analysis (EBUS sensitivity 86–97%) minimally changed κ (0.165–0.173). Conclusions: Station-level agreement between PET-CT and EBUS-TBNA is slight. PET has high patient-level sensitivity but poor specificity for N2/N3 disease, causing directional over-calling. EBUS-TBNA is necessary for PET-positive mediastinal nodes.

Outer Membrane–Peptidoglycan Anchoring in <i>Pseudomonas aeruginosa</i>

Journal of the American Chemical Society Amr M. El-Araby, Uxía Pérez de José, Vega Miguel-Ruano et al. Jul 01, 2026 DOI: 10.1021/jacs.6c03160

Expression and Localization of NMDA Receptor GluN2 Subunits in Dorsal Horn Pain Circuits across Sex, Species, and Late Postnatal Development

Journal of Neuroscience Katherine Griffiths, Jennifer Armstrong, Newton Martin et al. Jul 01, 2026 DOI: 10.1523/jneurosci.1174-25.2026

Despite being essential mediators of pain processing, the molecular identity of N -methyl- d -aspartate receptor (NMDAR) subtypes in nociceptive dorsal horn circuits is poorly understood, especially between sexes and in humans. Given the importance of GluN2 subunits in shaping NMDAR function and plasticity, we investigated the expression and localization of specific GluN2 NMDAR variants in the dorsal horn of viable spinal cord tissue from male and female rodents and human organ donors. Analysis of single-cell/nuclei sequencing datasets and quantitative reverse transcriptase polymerase chain reactions revealed that the GluN2A ( GRIN2A ) and GluN2B ( GRIN2B ) subunits are robustly expressed in dorsal horn neurons of mice, rats, and humans, with moderate expression of GluN2D ( GRIN2D ). Immunohistochemistry with antigen retrieval demonstrated that GluN2A, GluN2B, and GluN2D proteins are all preferentially localized to the superficial dorsal horn (SDH) of both adult rats and humans, which is conserved between males and females. Surprisingly, we found that these GluN2 NMDAR subunits are enriched in the lateral SDH in rats but not in humans, while presynaptic and neuronal markers are symmetrically distributed across the rat mediolateral axis. A dramatic shift in localization of GluN2A to the lateral SDH was observed across later postnatal development (PD21–PD90) in both male and female rats, with a corresponding change in synaptic NMDAR currents. This discovery of changes in NMDAR subunit distribution during maturation and between species will shed light on the physiological roles of NMDARs and their potential as therapeutic targets for pain.

FL-GQL: a fuzzy logic-guided Q-learning algorithm for global path planning of mobile robots in grid environments

Scientific Reports Gui-yan Liu, Zhou-qin Wang, Long-zhen Zhang et al. Jul 01, 2026 DOI: 10.1038/s41598-026-54255-z

High‐Energy‐Facet‐Oriented Mesoporous Single‐Crystal Metal Oxides for Selective Oxidation Catalysis

Advanced Materials Yangbo Dong, Tao Wang, Wei Li et al. Jul 01, 2026 DOI: 10.1002/adma.73641

ABSTRACT Mesoporous single‐crystal metal oxides are highly attractive for heterogeneous catalysis because they combine high surface accessibility with long‐range lattice coherence; however, their synthesis remains fundamentally challenging due to the thermodynamic incompatibility between crystallization and pore formation. Here we report a template‐free, energy‐driven facet‐oriented crystallization strategy that enables the formation of mesoporous single‐crystal metal oxides with tunable pore architectures and exposed high‐energy facets. Polyvinylpyrrolidone functions simultaneously as a pore maintainer and surface‐energy regulator, preserving mesoporosity while selectively stabilizing high‐energy facets to direct single‐crystal growth. The method is applicable to multiple oxides, including Co 3 O 4 , MgO, NiO, and mixed‐metal systems. As a representative example, mesoporous single‐crystal Co 3 O 4 with preferentially exposed (111) facets exhibits outstanding performance in the selective oxidation of aromatic alkanes, achieving up to 99% conversion and selectivity under mild conditions. Experimental and theoretical analyses suggest that the synergy between mesoporosity and active‐facet exposure enhances reactant adsorption, oxygen activation, and reaction kinetics, providing a general design principle for crystallographically defined porous catalysts.

Starvation-induced HSC70 O-GlcNAcylation activates chaperone-mediated autophagy

Journal of Biological Chemistry Ningda Xu, Xiangpeng Wang, Jiyue Zhang et al. Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113165

An oral anlotinib-capecitabine regimen plus penpulimab as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, phase 2 clinical trial.

Journal of Clinical Oncology Cheng Xu, Song Qu, Zhigang Liu et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.227

227 Background: Patients with NPC who progress after radical therapy often have poor prognosis and limited tolerance. Adding oral agents to chemo-immuno-targeted triplet therapy may enhance efficacy with reduced toxicity. Methods: This multicenter, single-arm, phase 2 trial evaluated first-line penpulimab (a PD-1 blockade) plus oral anlotinib (a tyrosine kinase inhibitor) and capecitabine in patients with R/M NPC previously treated with radical chemo/radiotherapy for non-metastatic disease. Patients from 4 academic hospitals in China received 4–6 cycles of penpulimab 200 mg IV d1, anlotinib 10 mg PO qd d1–14, and capecitabine 650 mg/m 2 PO bid d1–21 q3w, followed by penpulimab-capecitabine maintenance until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), overall survival (OS), safety, and quality of life (QoL). This trial was to be considered positive if the median PFS significantly reached an expected value of 11 mo than a historical threshold of 7 mo, with a 1-sided α of 2.5% and 80% power. This trial was registered with ClinicalTrials.gov (NCT05807880) and is now ongoing. Results: Between Sept 2023 and July 2025, 59 eligible patients (median [IQR] age, 50 [40–58] yrs; 33.9% women) were included, of which 23 (38.9%) and 41 (69.5%) patients had recurrent and metastatic diseases, respectively. Overall, 74.6% (44/59) of patients completed at least the required 4 cycles of the triple therapy. After a median follow-up of 10 mo (data cutoff: Nov 14, 2025), the median PFS was 13.5 mo (95% CI, 13.1–not reached [NR]) and the 12-mo PFS was 64.4% (95% CI, 50.3–78.5%). The median OS was NR, and the 12-mo OS was 87.8% (95% CI, 78.4–97.2%). As of Feb 10, 2026, ORR was 71.4% among 56 available patients, including 6 (10.7%) complete and 34 (60.7%) partial responses. Patients with baseline EBV DNA ≤ 4000 copies/mL had higher median PFS (NR vs 6.0 mo) and 12-mo PFS rate (71.3% vs 41.7%) than those with EBV DNA &gt; 4000 copies/mL ( p = 0.024). Twelve (20.3%) patients had grade 3–4 acute treatment-related adverse events (trAEs), with the most frequent trAE of palmar–plantar erythrodysesthesia (5.1%). Fifty-seven (96.6%) patients had all-grade trAEs, mainly including palmar–plantar erythrodysesthesia (39.0%), hypothyroidism (37.3%), stomatitis (33.9%), sore throat (32.2%), anemia (27.1%), and leukopenia (23.7%). Two treatment-related deaths were observed. Twenty-nine of 37 QoL domains (78.4%) remained stable or showed clinically meaningful improvement. Conclusions: A first-line combination of penpulimab with oral anlotinib-capecitabine has promising antitumor efficacy, low toxicity, and favorable QoL for patients with R/M NPC. Clinical trial information: NCT05807880 .

Correction to “Batch Discovery of Complex Metal Superhydrides via an Effective Machine Learning Method Structured by Chemical Template Concept”

Journal of the American Chemical Society Yuanhui Sun, Austin Ellis, Xin Chen et al. Jul 01, 2026 DOI: 10.1021/jacs.6c10805

Identifying predictors of mortality among the hospitalized road traffic injury patients: a retrospective case-control study (2022–2024)

Scientific Reports Somayeh Sadeghi, Sara Jambarsang, Mohammad Reza Khajehaminian et al. Jul 01, 2026 DOI: 10.1038/s41598-026-60256-9